Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.
- 31 January 1981
- Vol. 282 (6261) , 347-350
- https://doi.org/10.1136/bmj.282.6261.347
Abstract
Severely brittle diabetes is defined as a rare subtype of insulin-dependent diabetes with wide, fast, unpredictable, and inexplicable swings in blood glucose concentration, often culminating in ketoacidosis or hypoglycaemic coma. To assess the role of inappropriate type, amount, or timing of insulin treatment and the route of administration as a cause of severe brittleness six patients with continuous subcutaneous insulin infusion, which provides a high degree of optimisation of dosage with exogenous insulin in stable diabetics. The glycaemic control achieved during continuous subcutaneous insulin infusion was compared with that during continuous intramuscular insulin infusion. Six patients with non-brittle diabetes were also treated by continuous subcutaneous insulin infusion. These patients achieved the expected improvement in glycaemic control (mean +/- SD plasma glucose concentration 5.1 +/- 2.3 mmol/l (92 +/- 41 mg/100 ml)), but not the patients with brittle diabetes remained uncontrolled with continuous subcutaneous infusion (13.6 +/- 5.8 mmol/1 (245 +/- 105 mg/100 ml) compared with 10.3 +/- 4.1 mmol/l (186 +/- 74 mg/100 ml) during treatment with optimised conventional subcutaneous injections). During continuous intramuscular infusion, however, glycaemic control in five of the patients with brittle diabetes was significantly improved (7.7 +/- 2.6 mmol/l (139 +/- 47 mg/100 ml). The remaining patient with brittle diabetes, previously safely controlled only with continuous intravenous insulin, did not respond to continuous intramuscular infusion. It is concluded that in five of the six patients with brittle diabetes studied here impaired or irregular absorption of insulin from the subcutaneous site played a more important part in their hyperlability than inappropriate injection strategies. This absorption defect was presumably bypassed by the intramuscular route.This publication has 21 references indexed in Scilit:
- APROTININ AND INSULIN RESISTANCEThe Lancet, 1980
- continuous Subcutaneous Insulin Infusion in the Treatment of Diabetes MellitusDiabetes Care, 1980
- CONTINUOUS SUBCUTANEOUS INSULIN INFUSION: IMPROVED BLOOD-GLUCOSE AND INTERMEDIARY-METABOLITE CONTROL IN DIABETICSThe Lancet, 1979
- RESTORATION OF NORMAL LIPID AND AMINOACID METABOLISM IN DIABETIC PATIENTS TREATED WITH A PORTABLE INSULIN-INFUSION PUMPThe Lancet, 1979
- Continuous subcutaneous insulin Infusion: Good blood glucose control for up to 4 daysDiabetologia, 1979
- Reduction to Normal of Plasma Glucose in Juvenile Diabetes by Subcutaneous Administration of Insulin with a Portable Infusion PumpNew England Journal of Medicine, 1979
- Defective absorption of injected insulin.1978
- Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.BMJ, 1978
- 7 Brittle diabetesClinics in Endocrinology and Metabolism, 1977
- OBSERVATIONS ON ETIOLOGY + THERAPY OF BRITTLE DIABETES1964